Lisata Therapeutics GAAP EPS of -$2.40 beats by $0.22, revenue of $1M

Stock Information for Lisata Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lisata Therapeutics Inc.

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Lisata Therapeutics to Present at the 2025 BIO International Convention
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
Lisata Therapeutics Announces Research License with Catalent
Lisata Therapeutics to Present at the Investival Showcase USA
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.